Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases
- PMID: 16901023
- DOI: 10.4065/81.8.1013
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases
Abstract
Objective: To characterize the relationships between adherence (complance and persistence) to bisphosphonate therapy and risk of specific fracture types in postmenopausal women.
Patients and methods: Data were collected from 45 employers and 100 health plans in the continental United States from 2 claims databases during a 5-year period (January 1, 1999, through December 31, 2003). Claims from patients receiving a bisphosphonate prescription (alendronate or risedronate) were evaluated for 6 months before the Index prescription and during 24 months of follow-up to determine total, vertebral, and nonvertebral osteoporotic fractures, persistence (no gap in refills for >30 days during 24 months), and refill compliance (medication possession ratio > or = 0.80).
Results: The eligible cohort included 35,537 women (age, > or = 45 years) who received a bisphosphonate prescription. A subgroup with a specified diagnosis of postmenopausal osteoporosis was also evaluated. Forty-three percent were refill compliant, and 20% persisted with bisphosphonate therapy during the 24-month study period. Total, vertebral, nonvertebral, and hip fractures were significantly lower in refill-compliant and persistent patients, with relative risk reductions of 20% to 45%. The relationship between adherence and fracture risk remained significant after adjustment for baseline age, concomitant medications, and fracture history. There was a progressive relationship between refill compliance and fracture risk reduction, commencing at refill compliance rates of approximately 50% and becoming more pronounced at compliance rates of 75% and higher.
Conclusions: Adherence to bisphosphonate therapy was associated with significantly fewer fractures at 24 months. Increasing refill compliance levels were associated with progressively lower fracture rates. These findings suggest that incremental changes in medication-taking habits could improve clinical outcomes of osteoporosis treatment.
Comment in
-
A new look at osteoporosis outcomes: the influence of treatment, compliance, persistence, and adherence.Mayo Clin Proc. 2006 Aug;81(8):1009-12. doi: 10.4065/81.8.1009. Mayo Clin Proc. 2006. PMID: 16901022 No abstract available.
Similar articles
-
Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.Curr Med Res Opin. 2005 Sep;21(9):1453-60. doi: 10.1185/030079905X61875. Curr Med Res Opin. 2005. PMID: 16197664
-
Low frequency of treatment of osteoporosis among postmenopausal women following a fracture.Arch Intern Med. 2003 Sep 22;163(17):2052-7. doi: 10.1001/archinte.163.17.2052. Arch Intern Med. 2003. PMID: 14504118
-
Low incidence of anti-osteoporosis treatment after hip fracture.J Bone Joint Surg Am. 2008 Oct;90(10):2142-8. doi: 10.2106/JBJS.G.00864. J Bone Joint Surg Am. 2008. PMID: 18829912
-
Aging bone and osteoporosis: strategies for preventing fractures in the elderly.Arch Intern Med. 2003 Oct 13;163(18):2237-46. doi: 10.1001/archinte.163.18.2237. Arch Intern Med. 2003. PMID: 14557222 Review.
-
[Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].Ned Tijdschr Geneeskd. 2001 Jul 14;145(28):1336-8. Ned Tijdschr Geneeskd. 2001. PMID: 11484428 Review. Dutch.
Cited by
-
Persistence with intravenous zoledronate in elderly patients with osteoporosis.Osteoporos Int. 2012 Sep;23(9):2329-33. doi: 10.1007/s00198-011-1881-x. Epub 2011 Dec 17. Osteoporos Int. 2012. PMID: 22179417
-
Group medical consultation for osteoporosis: a prospective pilot study of patient experience in Canadian tertiary care.Br J Gen Pract. 2020 Oct 29;70(700):e801-e808. doi: 10.3399/bjgp20X713081. Print 2020 Nov. Br J Gen Pract. 2020. PMID: 33020167 Free PMC article.
-
Effects of Zoledronate on Mortality and Morbidity after Surgical Treatment of Hip Fractures.Adv Orthop. 2016;2016:3703482. doi: 10.1155/2016/3703482. Epub 2016 Mar 22. Adv Orthop. 2016. PMID: 27092280 Free PMC article.
-
Adherence to treatment of osteoporosis: a need for study.Osteoporos Int. 2007 Oct;18(10):1311-7. doi: 10.1007/s00198-007-0410-4. Epub 2007 Jun 22. Osteoporos Int. 2007. PMID: 17585359 Review.
-
Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment.Clin Interv Aging. 2009;4:357-65. doi: 10.2147/cia.s5637. Epub 2009 Oct 12. Clin Interv Aging. 2009. PMID: 19851511 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous